http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106377526-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-405 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-405 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate | 2016-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106377526-B |
| titleOfInvention | It is a kind of promote patients with cerebral apoplexy nerve regneration pharmaceutical composition and its application |
| abstract | The invention discloses a kind of pharmaceutical composition promoting patients with cerebral apoplexy nerve regneration and its application, which is oral preparation, is prepared by active constituent and pharmaceutic adjuvant, it is characterised in that：The active constituent includes N ' shown in following formula (2 (3 base of 1H indoles) acetyl group) aromatic hydrazide kind compound.The pharmaceutical composition of the present invention can inhibit the expression of nerve growth negative regulators by the expression of increase nerve growth positivity regulatory factor, promote the nerve regeneration of post-stroke, and then promote motion function rehabilitation. |
| priorityDate | 2016-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 47.